Company intelligence / Profile preview
Evopoint Biosciences
- Ownership
- Private
- Development stage
- Other
Overview
Evopoint has a robust pipeline with over seven clinical-stage programs and more than ten at discovery/preclinical stages. Lead asset XNW5004 is a selective EZH2 inhibitor in pivotal studies for relapsed/refractory PTCL and in combination trials with pembrolizumab for advanced solid tumors. Other assets include ADCs targeting CLDN18.2 and novel antibiotics/anti-infectives[6][8]. Interim results show promising efficacy and safety profiles.
- Therapeutic areas
- Metabolic DisordersOncologyInfectious Diseases
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs)Monoclonal antibodiesTargeted protein degraders (TPD/PROTACs)
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Evopoint Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evopoint Biosciences.